Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-1 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
22
Industry P/E
--
EV/EBITDA
-8.2
Div. Yield
0 %
Debt to Equity
0.7
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
4,357,960
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Deep Medicine Acquisition Corp (DMAQ)
| -74.4 | -74.4 | -74.4 | -71.1 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
Deep Medicine Acquisition Corp (DMAQ)
| 9.7 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Deep Medicine Acquisition Corp (DMAQ)
|
3.0 | 12.9 | 0.1 | -1.6 | -3,129.5 | -- | -- | 22.0 |
| 17.9 | -- | 8.2 | 17.5 | -38.0 | 4.4 | -- | 0.0 | |
| 11.9 | 572.8 | 423.6 | -513.2 | -71.9 | -35.9 | -- | 0.5 | |
| 8.6 | 577.1 | 1,873.6 | -229.3 | -5.1 | -40.9 | -- | 12.9 | |
| 9.0 | 633.8 | 290.1 | -6.4 | 4.5 | -6.5 | -- | 2.2 | |
| 22.1 | 458.6 | 42.5 | 4.6 | 18.7 | 1.1 | 96 | 0.9 | |
| 11.0 | 80.9 | 0.0 | -2.5 | -- | -- | -- | 1.0 | |
| 0.4 | 215.0 | 0.0 | 68.4 | -- | 35.6 | -- | 0.0 | |
| 10.3 | 320.5 | 0.0 | 6.5 | -- | 5.7 | 39.4 | 1.4 | |
| 16.8 | 720.5 | 0.5 | 34.9 | -2.9 | 7.2 | 16.6 | 1.2 |
Deep Medicine Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It... focuses on identifying businesses in the healthcare industry. Deep Medicine Acquisition Corp. was incorporated in 2020 and is based in New York, New York. Deep Medicine Acquisition Corp. operates as subsidiary of Bright Vision Sponsor LLC. Read more
CEO & Chairman of the Board
Mr. Humphrey P. Polanen
CEO & Chairman of the Board
Mr. Humphrey P. Polanen
Headquarters
New York, NY
Website
--
Our rating system has guided millions of investors in the past 20 years.
The share price of Deep Medicine Acquisition Corp (DMAQ) is $2.98 (NASDAQ) as of 31-Jan-2024 19:59 EDT. Deep Medicine Acquisition Corp (DMAQ) has given a return of -71.07% in the last 1 years.
Since, TTM earnings of Deep Medicine Acquisition Corp (DMAQ) is negative, P/E ratio is not available.
The P/B ratio of Deep Medicine Acquisition Corp (DMAQ) is 22.01 times as on 12-Feb-2024, a 449 premium to its peers’ median range of 4.01 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
The 52-week high and low of Deep Medicine Acquisition Corp (DMAQ) are Rs -- and Rs -- as of 03-Apr-2026.
Deep Medicine Acquisition Corp (DMAQ) has a market capitalisation of $ 13 Mln as on 12-Feb-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Deep Medicine Acquisition Corp (DMAQ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-5.41
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.